See Remarks
Todd Franklin Watanabe is the President, Chief Executive Officer, and a Class III director of Arcutis Biotherapeutics, Inc. (ARQT), positions he has held since April 2017.[[1]](https://fintool.com/app/research/companies/ARQT/people/todd-franklin-watanabe) At 57 years old, he has led the company through significant milestones, including multiple product launches for ZORYVE indications, achieving $166.5 million in net product revenue in 2024 (+471% YoY), and 128% attainment of corporate goals, despite a net loss of $(140.0) million.[[1]](https://fintool.com/app/research/companies/ARQT/people/todd-franklin-watanabe)
Watanabe brings extensive biotech experience from prior roles such as Co-founder and Chief Operating Officer at Kanan Therapeutics (2015–2018), VP of Strategy & Corporate Development at Kythera Biopharma (2013–2015), and various executive positions at Amgen (2005–2013) focusing on development and marketing for products like Repatha, Aimovig, and Enbrel.[[1]](https://fintool.com/app/research/companies/ARQT/people/todd-franklin-watanabe) Earlier, he worked at Eli Lilly and in the U.S. Government, complemented by 25 years as a U.S. Navy Reserve officer. He holds an M.A. in National Security Studies and a B.A. in International Relations from Georgetown University.[[1]](https://fintool.com/app/research/companies/ARQT/people/todd-franklin-watanabe) Recently, as a corporate insider, Watanabe has conducted stock transactions, including sales of shares under a 10b5-1 plan (e.g., 49,990 shares for ~$1.5M, 37,349 shares for tax withholding in March 2026), while retaining significant direct and indirect ownership.[[2]](https://www.marketbeat.com/instant-alerts/todd-watanabe-sells-19833-shares-of-arcutis-biotherapeutics-nasdaqarqt-stock-2026-02-04/)[[3]](https://www.investing.com/news/insider-trading-news/watanabe-todd-sells-arcutis-biotherapeutics-arqt-shares-for-15m-93CH-4376308)[[4]](https://www.stocktitan.net/sec-filings/ARQT/form-4-arcutis-biotherapeutics-inc-insider-trading-activity-39b7615e08ea.html)
View full insider profile →
Discussion